PMB-CT01 (PMB-101)
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL)
Phase 1Active
Key Facts
Indication
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL)
Phase
Phase 1
Status
Active
Company
About PeproMene Bio
PeproMene Bio is a private, clinical-stage biotech focused on developing BAFF-R-targeting immunotherapies for B-cell cancers and autoimmune disorders. Its lead asset, PMB-CT01 (BAFFR CAR-T), is in Phase 1 trials for relapsed/refractory B-ALL and mantle cell lymphoma, with early clinical data showing promise. The company leverages foundational intellectual property from City of Hope and MD Anderson and is supported by strategic partnerships and investment, positioning it to address antigen escape in CD19-targeted therapies.
View full company profileTherapeutic Areas
Other Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL) Drugs
| Drug | Company | Phase |
|---|---|---|
| lasme-cel (UCART22) | Cellectis | Phase 2 |